Implementing CAPP-Seq on blood samples of patients with early and advanced stage NSCLC, showed a high efficiency for detecting an allele frequency of EGFR mutations of down to 0.02% with >96% specificity [93,94]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.